Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 5—May 2020
Dispatch

Pretreatment Out-of-Pocket Expenses for Presumptive Multidrug-Resistant Tuberculosis Patients, India, 2016–2017

Priya RathiComments to Author , Kalpita Shringarpure, Bhaskaran Unnikrishnan, Vineet Kumar Chadha, Vishak Acharya, Abirami Nair, Karuna D. Sagili, and Suresh Shastri
Author affiliations: Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India (P. Rathi, B. Unnikrishnan, V. Acharya, A. Nair); Medical College Baroda, Baroda, India (K. Shringarpure); Central Leprosy Teaching and Research Institute, Tamil Nadu, India (V.K. Chadha); National Tuberculosis Institute, Epidemiology and Research, Division Bengaluru, India (V.K. Chadha); International Union against Tuberculosis and Lung Disease, South East Asia Office, New Delhi, India (K.D. Sagili); Lady Willington State TB Centre, Bengaluru (S. Shastri)

Main Article

Figure 1

Flow chart showing patient enrollment in study of pretreatment out-of-pocket expenses for presumptive multidrug-resistant tuberculosis patients, India, 2016–2017.

Figure 1. Flow chart showing patient enrollment in study of pretreatment out-of-pocket expenses for presumptive multidrug-resistant tuberculosis patients, India, 2016–2017.

Main Article

Page created: April 16, 2020
Page updated: April 16, 2020
Page reviewed: April 16, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external